ÂÜÀòÂÒÂ×

Kenneth Kang serves as the Suzhou M1 General Manager and Senior Vice President at Innovent Biologics since October 2018, having previously held the position of Head/Vice President of Manufacturing at Generon (Shanghai) Corporation. Prior experience includes directorship in Process Development at Thermo Fisher Scientific, where responsibilities encompassed the development and scale-up of mammalian cell culture processes. As a Principal Scientist at Eli Lilly and Company, Kenneth focused on bioprocess sciences, technology development, and antibodies, alongside publishing significant research in pharmaceutical bioprocessing. Previous roles also include Investigator at Progenics Pharmaceuticals, where patents were filed related to antibodies for infectious diseases, and Senior Scientist at Wyeth Pharmaceuticals, specializing in purification processes. Kenneth holds a Ph.D. in Bioseparation from the New Jersey Institute of Technology.